- Home
- CHEB vs ACRS Comparison
CHEB vs ACRS Comparison
Compare CHEB & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHEB
- ACRS
- Stock Information
- Founded
- CHEB 2024
- ACRS 2012
- Country
- CHEB Singapore
- ACRS United States
- Employees
- CHEB N/A
- ACRS N/A
- Industry
- CHEB
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- CHEB
- ACRS Health Care
- Exchange
- CHEB NYSE
- ACRS Nasdaq
- Market Cap
- CHEB 122.8M
- ACRS 127.6M
- IPO Year
- CHEB 2024
- ACRS 2015
- Fundamental
- Price
- CHEB $7.92
- ACRS $1.46
- Analyst Decision
- CHEB
- ACRS Strong Buy
- Analyst Count
- CHEB 0
- ACRS 8
- Target Price
- CHEB N/A
- ACRS $9.71
- AVG Volume (30 Days)
- CHEB 24.6K
- ACRS 709.4K
- Earning Date
- CHEB 01-01-0001
- ACRS 05-08-2025
- Dividend Yield
- CHEB N/A
- ACRS N/A
- EPS Growth
- CHEB N/A
- ACRS N/A
- EPS
- CHEB N/A
- ACRS N/A
- Revenue
- CHEB N/A
- ACRS $17,777,000.00
- Revenue This Year
- CHEB N/A
- ACRS N/A
- Revenue Next Year
- CHEB N/A
- ACRS $14.59
- P/E Ratio
- CHEB N/A
- ACRS N/A
- Revenue Growth
- CHEB N/A
- ACRS N/A
- 52 Week Low
- CHEB $6.09
- ACRS $0.99
- 52 Week High
- CHEB $13.70
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- CHEB N/A
- ACRS 61.33
- Support Level
- CHEB N/A
- ACRS $1.22
- Resistance Level
- CHEB N/A
- ACRS $1.56
- Average True Range (ATR)
- CHEB 0.00
- ACRS 0.09
- MACD
- CHEB 0.00
- ACRS 0.03
- Stochastic Oscillator
- CHEB 0.00
- ACRS 75.00
About CHEB CHENGHE ACQUISITION II CO
Chenghe Acquisition II Co is a blank check company.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.